Ryunosuke Machida

Impact of Achieving Progression‐Free Survival 24 on Subsequent Overall Survival in Diffuse Large B‐Cell Lymphoma Patients

Ayumi Fujimoto, Wataru Munakata, Gakuto Ogawa, Ryunosuke Machida et autres

The impact of achieving progression-free survival at 24 months (PFS24) on subsequent survival in patients with diffuse large B-cell lymphoma (DLBCL) relative to the general population remains debatable. We assessed the impact of achieving PFS24 in newly diagnosed DLBCL patients using data …

jp (code pays fourni par la source)

Study protocol of a randomized controlled phase II trial comparing nivolumab, ipilimumab plus radiotherapy versus nivolumab plus ipilimumab for advanced or recurrent esophageal cancer: Japan Clinical Oncology Group study JCOG2311 (ART NOUVEAU)

Katsuyuki Sakanaka, Keita Sasaki, Takahiro Tsushima, Ryunosuke Machida et autres

BACKGROUND: The immunogenic cell death induced by radiotherapy (RT) has been demonstrated to enhance the systemic antitumor effect of immune checkpoint inhibitors (ICIs). The incorporation of RT into ICIs has the potential to mitigate the occurrence of early treatment failure, particularly with …

jp, us (code pays fourni par la source)

10011-CS-2 A Phase II basket trial evaluating the efficacy of tasurgratinib in patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alteration (FORTUNE study)

Masamichi Takahashi, Kazuki Sudo, Junichi Matsubara, Kenji Tsuchihashi et autres

Abstract Background Tasurgratinib is orally available selective FGFR1-3 tyrosine kinase inhibitor approved in Japan for biliary tract cancer with FGFR2 fusions or rearrangements. We previously identified highly sensitive FGFR mutations to tasurgratinib using a high-throughput functional evaluation method (MANO method). We conducted …

jp, us (code pays fourni par la source)

Protocol digest of a randomized phase III study of pola-R-CHP/high-dose methotrexate/IT vs. pola-R-CHP/IT for newly diagnosed diffuse large B-cell lymphoma with high risk of central nervous system relapse: JCOG2201 (PREMIER)

Y. Sano, Kana Miyazaki, Motoko Yamaguchi, Senzo Taguchi et autres

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Central nervous system (CNS) relapse is an uncommon yet lethal event in patients with DLBCL. Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisolone (pola-R-CHP) is a standard of care for …

jp, us (code pays fourni par la source)

Role of bortezomib maintenance therapy in the anti-CD38 antibody era: Interim analysis results of a randomized Phase III study for transplant-ineligible newly diagnosed multiple myeloma (JCOG1911/B-DASH Study)

Tomotaka Suzuki, Ryunosuke Machida, Yusuke Sano, Kazuyuki Shimada et autres

Abstract Introduction Daratumumab (Dara) plus melphalan, prednisolone, and bortezomib (Bor) (D-MPB), followed by Dara maintenance therapy, has become one of the standard of care for transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM) based on the ALCYONE trial. However, a steep decrease in …

jp, us (code pays fourni par la source)

Pembrolizumab Plus Lenvatinib in the Treatment of Unresectable Cutaneous Angiosarcoma: A study protocol of Multicenter, Open-label Phase II Study (NCCH2213, PLAS)

Dai Ogata, Eiji Nakano, Naoya Yamazaki, Takeru Funakoshi et autres

us, jp (code pays fourni par la source)

155. INTER-INSTITUTIONAL SURVIVAL HETEROGENEITY BETWEEN SURGERY AND CHEMORADIOTHERAPY FOR CLINICAL STAGE I ESOPHAGEAL CANCER: EXPLORATORY ANALYSIS OF JCOG0502

Kazuhiro Shiraishi, Ken Kato, Ryunosuke Machida, Keita Sasaki et autres

Abstract Background Surgery and chemoradiotherapy (CRT) are treatment options for clinical stage I esophageal squamous cell carcinoma (ESCC). However, the distribution of these treatments varies among institutions, potentially contributing to differences in outcomes between high- and low-volume centers. JCOG0502, a parallel-group controlled …

us, jp (code pays fourni par la source)

The phase II study of pembrolizumab plus lenvatinib for patients with unresectable cutaneous angiosarcoma (Pembro-Lenva for cAS/PLAS trial).

Dai Ogata, Eiji Nakano, Takeru Funakoshi, Akira Takahashi et autres

TPS11586 Background: Cutaneous angiosarcoma (cAS) is a rare cancer that often occurs in elderly people with common recurrence and metastasis after surgery. Chemotherapy, radiation therapy, and their combination are widely used, but their effectiveness is insufficient. With the increasing number of cAS …

jp (code pays fourni par la source)

Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study

Noriko Fukuhara, Dai Maruyama, Kenichi Ishizawa, Y. Sano et autres

Background: Watchful waiting (WW) is thought to be a reasonable initial approach for low-tumor-burden follicular lymphoma (LTB-FL), although there is an increased risk of adverse clinical events, including progression to high tumor burden (HTB), resulting in exposure to cytotoxic chemotherapy and histological …

jp (code pays fourni par la source)

Multicenter randomized phase III study of high-dose therapy with autologous stem cell transplantation versus observation for patients with newly diagnosed peripheral T-cell lymphoma who achieved complete metabolic response after induction therapy (JCOG2210, TRANSFER study)

Ryosuke Kita, Kazuyuki Shimada, Ryunosuke Machida, Tetsuya Sekita et autres

Patients with peripheral T-cell lymphoma demonstrated a poor prognosis after obtaining a complete response with induction treatment compared to those with B-cell lymphoma. Once it relapsed, curative treatment is frequently limited to invasive treatments with significant treatment-related mortality, including allogeneic stem cell …

jp, us (code pays fourni par la source)

Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group

Atsuo Takashima, Megumi Ishiguro, Keita Sasaki, Ryunosuke Machida et autres

BACKGROUND: Although treatment outcomes for metastatic colorectal cancer (mCRC) have dramatically improved over the past few decades, drug costs have also significantly increased. This study aimed to investigate which first-line treatment regimens for mCRC are actually used (frequency) in Japanese practice and …

us, jp (code pays fourni par la source)

Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial

Ken Kato, Ryunosuke Machida, Yoshinori Ito, Hiroyuki Daiko et autres

us, jp (code pays fourni par la source)